You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T Cell Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Fanconi Anemia, Severe Aplastic Anemia, MDS Trial in Minneapolis (Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY)

Recruiting
  • Fanconi Anemia
  • +2 more
  • Total Body Irradiation (TBI) (Plan 1)
  • +8 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Nov 2, 2022

Blood Cancer Trial (KCAT19 T cells)

Not yet recruiting
  • Blood Cancer
  • KCAT19 T cells
  • (no location specified)
May 20, 2022

Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))

Recruiting
  • Pancreatic Cancer
  • TCR-T Cells Injection（GB3010 Cells Injection）
  • ShangHai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting
  • Hematologic Malignancy
  • +21 more
  • (no location specified)
Feb 9, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

Recruiting
  • Advanced Solid Tumor
  • Bethesda, Maryland
  • +1 more
Jan 6, 2023

Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte

Recruiting
  • Lymphoid Leukemia, Acute
  • +2 more
  • T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc
May 24, 2022

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Kita-kyushu Lung Cancer Antigen 1, Human Trial run by the NCI (IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR)

Recruiting
  • Kita-kyushu Lung Cancer Antigen 1, Human
  • IL-2 (Aldesleukin)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 27, 2022

Prostate Specific Antigens, Prostate Tumors Trial run by the National Cancer Institute (NCI) (TARP peptide vaccine, TARP

Completed
Has Results
  • Prostate Specific Antigens
  • Prostate Neoplasms
  • T-cell receptor alternate reading frame protein (TARP) peptide vaccine
  • T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 15, 2022

ALLoreactive T-Cell receptOr RePertoire in kidnEy

Recruiting
  • Renal Transplant Rejection
  • +3 more
  • Mixed lymphocyte reaction
  • Vienna, Austria
    Medical university of Vienna
Apr 5, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy Trial in New Brunswick (Conditioning, E7 TCR-T

Not yet recruiting
  • HPV-Associated Cervical Carcinoma
  • +16 more
  • Conditioning, E7 TCR-T cells, and aldesleukin
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 17, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))

Completed
  • Hepatocellular Carcinoma
  • TCR-T
  • No intervention and TCR-T (at crossover)
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital, Sun-Yat Sen University
Jun 27, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023